Maysiglu

Sitagliptin, the active ingredient in Maysiglu, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is prescribed to improve blood‑glucose control in adults with type 2 diabetes mellitus, usually as part of a comprehensive treatment plan that includes diet and exercise. Maysiglu is marketed in the European Union and is available only by prescription.

GNH USA supplies Maysiglu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is used to manage hyperglycaemia in the type 2 diabetes mellitus therapeutic pathway.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Monotherapy: provides glycaemic control when used alone in patients inadequately controlled by diet and exercise. - Combination therapy: enhances glucose control when added to metformin or other antidiabetic agents.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Gastrointestinal upset: includes nausea, diarrhoea, or abdominal discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including rash, angioedema, or anaphylaxis. - Bullous pemphigoid: rare skin blistering condition. - Hepatic injury: signs of liver dysfunction such as jaundice. - Hypersensitivity reactions: including fever, eosinophilia, or organ involvement.

Before initiating therapy with sitagliptin, consider the following precautions.

- Renal function: dose adjustment may be required in patients with impaired renal clearance. - Hepatic impairment: monitor liver enzymes in patients with existing liver disease. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor blood glucose closely. - History of pancreatitis: avoid use or discontinue promptly if symptoms recur. - Elderly patients: start at the lowest effective dose and monitor for adverse effects. - Store at ambient temperature: keep below 25 °C, retain in the original container, and protect from moisture.

Sitagliptin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other DPP‑4 inhibitors: concurrent use can lead to excessive DPP‑4 inhibition and increased adverse events. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: heightened risk of hypoglycaemia; adjust dose as needed. - Rifampin: induces metabolism and may reduce sitagliptin exposure. - Ketoconazole: can increase sitagliptin concentrations; monitor for side effects. - Diuretics (e.g., furosemide): may affect renal clearance; observe renal function.